Cancer Science & Therapy

Abraham Degaga Abdi

Publications

• Review Article
  Potential Molecular Targets and Drugs for Treatment of Hepatocellular Carcinoma
  Author(s): Abraham Nigussie Mekuria and Abraham Degaga AbdiAbraham Nigussie Mekuria and Abraham Degaga Abdi
  
  Hepatocellular Carcinoma (HCC) is a common type of primary liver cancer. According to the recent world cancer report, the disease ranked as the sixth most common cancer worldwide and the third largest cause of cancer-related death. Deregulation of numerous signaling pathways have been implicate in pathogenesis of HCC, including IGF, EGF/TGF, HGF/cMet, WNT, Hedgehog, notch, hippo, VEGF, PDGF, and FGF. Besides, intracellular mediators such as MAPK and PI3K/AKT/mTOR play a role in HCC development and progression. Currently sorafenib is the only molecularly targeted drug available to treat advanced HCC. It only extends survival by a matter of months. Moreover, there is no alternative agent for patients progressing under treatment with sorafenib. Thus, there remains a critical need for both continued molecular characterization and aggressive drug development. This review provided and updat.. Read More»
  DOI: 10.4172/1948-5956.1000501

  Abstract PDF